Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JAB 23E73

Next Previous
Drug Profile

JAB 23E73

Alternative Names: JAB-23E73

Latest Information Update: 10 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jacobio Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma; Solid tumours

Most Recent Events

  • 10 Sep 2026 Phase-I/II clinical trials in Adenocarcinoma (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in China (PO) (NCT07640295)
  • 16 Jul 2026 Phase-I/II clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, First-line therapy, Late-stage disease) in China (IV) (NCT07640295)
  • 10 Jun 2026 Jacobio Pharmaceuticals plans a phase I/II trial for Pancreatic ductal adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease, First line therapy) in China (PO, Tablet) in June 2026 (NCT07640295)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top